Study Complete
Sponsor ID
20080537
Extension Study to Evaluate Long Term Safety of Denosumab in Subjects Undergoing ADT for Non-Metastatic Prostate Cancer
Study Details
The purpose of this study is to describe the safety and tolerability of up to 5 years (ie, 3 years under the 20040138 Amgen study and 2 years on this study) denosumab administration as measured by adverse events, immunogenicity, and safety laboratory parameters in subjects who previously received denosumab for non-metastatic prostate cancer.
Protocol Summary
Primary Outcome Measures
Safety endpoints in subjects previously treated with denosumab who receive up to 5 years of denosumab administration.
Timeframe: 24 months
Secondary Outcome Measures
Safety endpoints in subjects previously treated with placebo who receive up to 2 years of denosumab administration.
Timeframe: 24 months
Study Documents
Study Synopsis
Available Language(s): English
Locations
Location
Research Site
Santa Monica, CA, United States, 90404
Status
Recruiting
Location
Research Site
Anaheim, CA, United States, 92801
Status
Recruiting
Location
Research Site
San Bernardino, CA, United States, 92404
Status
Recruiting
Location
Research Site
Dallas, TX, United States, 75231
Status
Completed
Location
Research Site
Omaha, NE, United States, 68114
Status
Recruiting
Location
Research Site
Middlebury, CT, United States, 06762
Status
Recruiting
Showing {first} - {last} of {total} Results